Filing summary
Issuer identification: The filing is Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN), not Cervomed Inc. It is a Form 10-Q for the quarter ended June 30, 2021, filed August 11, 2021. The financial statements are unaudited.
Business context and reporting period
Diffusion is a clinical-stage biopharmaceutical company developing trans sodium crocetinate (TSC) to improve oxygen delivery to hypoxic tissues; DFN-529 is also in early-stage development. The company has no product revenue and continues to fund operations primarily through equity financings.
Financial results and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| R&D expense | $1.97 million | $2.17 million | $4.89 million | $3.71 million |
| G&A expense | $1.84 million | $1.46 million | $3.58 million | $2.85 million |
| Net loss | $3.78 million | $3.13 million | $8.42 million | $5.68 million |
| Net loss per share | $0.04 | $0.10 | $0.09 | $0.18 |
| Operating cash used | Not separately stated | Not separately stated | $8.50 million | $6.65 million |
At June 30, cash and cash equivalents were $43.31 million, versus $18.52 million at December 31, 2020. Working capital was $41.8 million; current liabilities were $2.10 million. Total liabilities were $2.54 million, mainly current payables, accruals, lease liabilities, and deferred taxes; the company reported no credit facilities or committed borrowing. Accumulated deficit was $114.33 million. Management expects existing cash to fund operating and capital requirements, including planned trials, through 2023, while stating that additional funding will be needed to complete TSC development.
Six-month financing cash inflow was $33.30 million: $31.09 million net proceeds from the February 2021 stock offering and $2.20 million from warrant exercises. Shares outstanding rose from 64.02 million at year-end 2020 to 101.90 million at June 30, 2021. No revenue-based margins are applicable.
Material changes versus comparable periods
- Six-month net loss increased by $2.74 million year over year, principally reflecting higher R&D and G&A spending and the absence of the prior-year income tax benefit.
- Six-month R&D expense rose $1.18 million, including TCOM and COVID trial costs, increased manufacturing costs and payroll; costs from winding down glioblastoma and stroke trials partly offset the increase.
- Six-month G&A expense rose $0.73 million, mainly due to higher compensation, stock-based compensation, headcount and insurance. Some costs related to former executive separations were described as nonrecurring.
- Cash increased substantially following the February 2021 public offering and warrant exercises, with significant corresponding share issuance and potential dilution.
Outlook, risks and unusual items
- Management reported a positive dose-response trend in TCOM readings in 30 healthy volunteers, with no evidence of hyperoxygenation; TSC was reported safe and well tolerated at tested doses. These are topline findings, not evidence of clinical efficacy.
- The COVID trial was completed in February 2021. Although not designed or powered to establish efficacy, the safety monitoring committee observed improved secondary and exploratory outcomes at the 1.5 mg/kg dose compared with lower doses.
- Management planned the Altitude Trial for Q4 2021, with results expected one to two months after completion. The ILD-DLCO trial was expected to start in late Q4 2021 and complete in Q1 2022. The company expected to identify an initial indication in Q4 2021 and begin a Phase 2 trial in the first half of 2022. These are forward-looking plans, not guarantees.
- The company expects substantial continuing losses and R&D spending. It cautions that failure to obtain additional financing could delay or curtail development, require collaborations or strategic alternatives, or force cessation of operations; future equity financing may dilute existing holders.
- A former executive’s arbitration matter remained unresolved, with a hearing scheduled for August 16, 2021. The company said it could not estimate the possible loss or range of loss and noted the outcome could materially affect financial position, results or cash flows.
- Management said disclosure controls were effective and there were no material changes in internal control over financial reporting during the quarter. It reported no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for Diffusion Pharmaceuticals Inc. (DFFN), despite the request metadata naming Cervomed Inc.
- Track whether the planned trials began and completed on schedule, and assess full results rather than preliminary trends or exploratory observations.
- Assess cash burn against management’s stated runway through 2023 and the funding required for later-stage development.
- Review dilution from the 2021 offering, warrant exercises, outstanding warrants and potential future financing.
- Check the status and potential financial effect of the former executive arbitration, which the filing did not quantify.